PET Tau - Neurodegenerative Disease Imaging

Status Recruiting

Clinical Trial Summary

Clinical Trial Description

The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells, including Alzheimer's disease, Parkinson's disease, Lewy body disease and Frontotemporal degeneration. 18F-AV-1451 (formally known as 18F-T807) is a specialized radioactive PET tracer that sticks to the tau protein in the brain. In this study, researchers will use 18F-AV-1451 to form images of tau binding in the brain. 18F-AV-1451 is an investigational or experimental imaging agent that has not yet been approved by the Food and Drug Administration for use in brain imaging. In this study, researchers want to find out how accurate and useful 18F-AV-1451 is in imaging patients who have problems with thinking, remembering, speech, and visual activities, and may be diagnosed with different types of neurodegenerative disease. This study will help test how imaging measures may provide information that could be used to determine diagnosis for patients in the future. The results of the PET/CT scan will be compared with other information obtained under related protocols, including brain magnetic resonance imaging (MRI), spinal fluid and cognitive test results. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03143374
Study type	Interventional
Source	University of Pennsylvania
Contact	Dahlia Kamel
Phone	215-662-6134
Email	kamel.dahlia@pennmedicine.upenn.edu
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	September 2016
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02402426` - Brain Health Registry: An Online Registry to Identify and Assess Subjects for Brain Research
Completed	`NCT00714636` - Cerebrospinal Fluid Repository	N/A
Active, not recruiting	`NCT00907283` - Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)	Phase 2
Terminated	`NCT00718003` - Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS).	N/A
Completed	`NCT00016562` - Cause and Pathogenesis of Neurometabolic Disorders	N/A
Terminated	`NCT00718445` - Pennsylvania Consortium: Clinical Database	N/A
Recruiting	`NCT02869048` - Amyotrophic Lateral Sclerosis and the Innate Immune System	N/A
Completed	`NCT00718393` - Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS)	N/A
Terminated	`NCT00718107` - Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology	N/A
Completed	`NCT00001365` - Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System	Phase 2
Recruiting	`NCT00271622` - The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
Completed	`NCT01758510` - Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis	Phase 1
Terminated	`NCT00718016` - Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient	N/A
Completed	`NCT00718497` - Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population	N/A
Completed	`NCT00718458` - EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS)	N/A
Completed	`NCT02418546` - Electronic-health Application To Measure Outcomes REmotely Clinical Trial	N/A
Completed	`NCT00716131` - Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program	N/A